Real-world Evidence Study on the Early Use of Cemiplimab in the UK: REACT-CEMI (Real World Evidence of Advanced CSCC Treatment - With CEMIplimab)
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Cemiplimab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REACT-CEMI
- Sponsors Sanofi
Most Recent Events
- 13 Jul 2023 Status changed from active, no longer recruiting to completed.
- 11 Aug 2022 New trial record